A prospective, randomized trial comparing thulium vapoenucleation with holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic obstruction: perioperative safety and efficacy

World J Urol. 2017 Dec;35(12):1913-1921. doi: 10.1007/s00345-017-2071-z. Epub 2017 Jul 11.

Abstract

Introduction and objectives: To compare the perioperative outcomes of thulium vapoenucleation of the prostate (ThuVEP) with holmium laser enucleation of the prostate (HoLEP) for patients with symptomatic benign prostatic obstruction (BPO).

Methods: Forty-eight and 46 patients were prospectively randomized to ThuVEP and HoLEP. All patients were assessed preoperatively and 4-week postoperatively. The complications were noted and classified according to the modified Clavien classification system. Patient data were expressed as median (interquartile range) or numbers (%).

Results: Median age at surgery was 73 (67-76) years and median prostate volume was 80 (46.75-100) cc and not different between the groups (p = 0.207). The median operative time was 60 (41-79) minutes without significant differences between both groups (p = 0.275). There were no significant differences between the groups regarding catheterization time [2 (2-2) days, p = 0.966] and postoperative stay [2 (2-3) days, p = 0.80]). Clavien 1 (13.8%), Clavien 2 (3.2%), Clavien 3a (2.1%), and Clavien 3b (4.3%) complications occurred without significant differences between the groups. However, the occurrence of acute postoperative urinary retention was higher after HoLEP compared to ThuVEP (15.2 vs. 2.1%, p ≤ 0.022). At 1-month follow-up, peak urinary flow rates (10.7 vs. 22 ml/s), post-void residual volumes (100 vs. 20 ml), International Prostate Symptom Score (20 vs. 10) and Quality of Life (4 vs. 3) had improved significantly (p ≤ 0.005) without significant differences between the groups.

Conclusions: ThuVEP and HoLEP are safe and effective procedures for the treatment of symptomatic BPO. Both procedures give equivalent and satisfactory immediate micturition improvement with low perioperative morbidity.

Keywords: Benign prostatic obstruction, BPO; Ho:YAG; HoLEP; Laser surgery; Prostate; ThuVEP; Tm:YAG; VapoEnucleation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Humans
  • Laser Therapy* / adverse effects
  • Laser Therapy* / instrumentation
  • Laser Therapy* / methods
  • Lasers, Solid-State / therapeutic use*
  • Male
  • Operative Time
  • Patient Preference
  • Postoperative Complications* / diagnosis
  • Postoperative Complications* / etiology
  • Prostatectomy* / adverse effects
  • Prostatectomy* / instrumentation
  • Prostatectomy* / methods
  • Prostatic Hyperplasia* / diagnosis
  • Prostatic Hyperplasia* / physiopathology
  • Prostatic Hyperplasia* / surgery
  • Prostatism* / etiology
  • Prostatism* / surgery
  • Thulium / therapeutic use*
  • Treatment Outcome

Substances

  • Thulium